Inactive Instrument

Press Releases BioTime, Inc. Nyse

Equities

US09066L1052

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lineage Cell Therapeutics : Immediate Report	09:26pm	PU
Lineage Cell: Q1 Earnings Snapshot	10/05	AQ
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	10/05	BU
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	07/05	AQ
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05	BU
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	02/05	BU
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE	01/05	AQ
Lineage Cell Therapeutics : Immediate Report	30/04	PU
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	30/04	PU
Lineage Cell Therapeutics : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY	30/04	PU
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)	30/04	BU
Lineage Announces Changes to Board of Directors	30/04	BU
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development	01/04	BU
Lineage Cell Therapeutics : Immediate Report	24/03	PU
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium	18/03	BU
LINEAGE CELL THERAPEUTICS, INC. - RG6501 PHASE 1/2A CLINICAL STUDY 24 MONTH RESULTS TO BE FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	14/03	AQ
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	13/03	BU
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting	11/03	BU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III	10/03	PU
Lineage Cell Therapeutics : FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Cukkey Brian M	10/03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioTime, Inc. Nyse

Equities

US09066L1052

Press Releases

Filters